Gastroenterology Research and Practice

Research Article

Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery

Table 2

Treatment information on chemotherapy and surgery, hazard ratios, and values from univariable survival analysis ().


	(%)	Hazard ratio (95% CI)	value

Neoadjuvant regimen
mFLOT	121 (56.3%)	Reference
SOX, XELOX or FOLOFX	78 (36.3%)	0.45 (0.19-1.05)	0.07
Other	16 (7.4%)	0.39 (0.15-1.02)	0.05
Cycles received	4 (4-4)	1.08 (0.88-1.34)	0.45
Time gap between NAC and surgery (days)		1.03 (1-1.05)	0.07
Resection extend
Total gastrectomy	129 (60%)	Reference	—
Subtotal gastrectomy	86 (40%)	0.76 (0.39-1.47)	0.42
Laparoscopic surgery
Yes	167 (77.7%)	Reference	—
No	48 (22.3%)	1.45 (0.76-2.78)	0.26
Metastasis found during surgery
Yes	7 (3.3%)	Reference	—
No	208 (96.7%)	0.83 (0.11-6.08)	0.83
Multivisceral resection
Yes	25 (11.6%)	Reference	—
No	190 (88.4%)	0.64 (0.26-1.54)	0.32
R0 resection
Yes	190 (88.4%)	Reference	—
No	25 (11.6%)	0.40 (0.20-0.83)	0.01
Major complication
No	191 (88.8%)	Reference	—
IIIa	24 (11.2%)	0.67 (0.21-2.18)	0.51
Reoperation within 30 days
Yes	5 (2.3%)	Reference	—
No	210 (97.7%)	0.72 (0.19-10+)	0.75
Adjuvant chemotherapy
No	17 (7.9%)	Reference	—
Yes	198 (92.1%)	0.27 (0.12-0.62)	<0.01
Cycles received	5 (3-5)	0.88 (0.78-1)	0.05
Time between surgery and adjuvant chemotherapy (days)		1.03 (1-1.05)	0.07

mFLOT: docetaxel 50~60 mg/m² + oxaliplatin 85 mg/m² + fluorouracil 2800 mg/m² iv over 48 hours, every 2 weeks; SOX: oxaliplatin 130 mg/m² iv + tegafur/gimeracil/oteracil potassium capsule 40~60 mg bid D1-D14 every 3 weeks; XELOX: oxaliplatin 130 mg/m² + capecitabine 1000 mg/m² bid D1-D14 every 3 weeks; FOLFOX: oxaliplatin 85 mg/m² + fluorouracil 2800 mg/m² civ over 48 hours every 2 weeks. The dosage of the regimens above might be modified according to the preference of the oncologist. NAC: neoadjuvant chemotherapy. Major complication is defined according to the Clavien-Dindo Classification system (Grade III and above): Grade III, complications requiring surgical, endoscopic, or radiological intervention (IIIa: no general anesthesia required; IIIb: general anesthesia required); Grade IV, life-threatening complications requiring IC/ICU management; Grade V, death.